CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Ozone auto-hemotherapyWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D011014 Pneumonia NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 A Trial of Ozone Auto-hemotherapy in Adults Hospitalized With Covid-19 Pneumonia

This is a multicenter, randomized, controlled, open-label clinical trial testing the use of ozone auto-hemotherapy in hospitalized patients with Covid-19 pneumonia. Eligible patients will be randomly assigned to receive either ozone auto-hemotherapy plus standard treatment, or standard treatment alone. Patients in the ozone auto-hemotherapy group will receive treatment mixing 100-200ml of blood with ozone at a concentration of 40 μg / mL with a gas volume of 200 ml. Treatment will occur every 12h during 5 days. Standard treatment will be the one used in each hospital participating in the trial. All analyses will be done according to the intention-to-treat principle

NCT04370223 COVID-19 Pneumonia Biological: Ozone auto-hemotherapy
MeSH:Pneumonia
HPO:Pneumonia

Primary Outcomes

Description: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)

Measure: Rate of patients achieving improvement in clinical condition at day 14 after recruitment

Time: 14 days

Secondary Outcomes

Description: mortality

Measure: Mortality at day 28

Time: 28 days

Description: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)

Measure: Rate of patients achieving improvement in clinical condition at day 28 after recruitment

Time: 28 days

Description: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)

Measure: Rate of patients achieving improvement in clinical condition at day 7 after recruitment

Time: 7 days

Description: Improved clinical condition defined by an improvement of 2 points in the clinical status, 8 categories, ordinary score of the World Health Organization (WHO)

Measure: Time to clinical improvement or hospital discharge

Time: 28 days

Description: Ventilator-free days from last extubation day until day 28 after recruitment

Measure: Number of ventilator-free days at 28 days

Time: 28 days

Description: Days hospitalized

Measure: Hospital length of stay

Time: 28 days

Description: Number of days until a 2-fold decrease in ferritin (ng/mL)

Measure: Time to a 2-fold decrease in ferritin

Time: 14 days

Description: Number of days until a 2-fold decrease in C-Protein Reactive (mg/L)

Measure: Time to a 2-fold decrease in C-protein reactive

Time: 14 days

Description: Number of days until a 2-fold decrease in Dimer-D (ng/mL)

Measure: Time to a 2-fold decrease in Dimer-D

Time: 14 days

Description: Number of days until a 2-fold decrease in Lactate Dehydrogenase (U/L)

Measure: Time to a 2-fold decrease in Lactate Dehydrogenase

Time: 14 days

Description: Number of days until a 2-fold decrease in Neutrophils to Lymphocytes ratio

Measure: Time to a 2-fold decrease in Neutrophils to Lymphocytes ratio

Time: 14 days

Related HPO nodes (Using clinical trials)

HP:0002090: Pneumonia
Genes 208
TIMM8A DNAH9 GAS8 DNAH11 TNFRSF11A TBC1D24 SPAG1 MS4A1 GAS2L2 CCDC151 NIPBL BTK LIG4 NFKB2 TCIRG1 IGLL1 RNF168 STAT3 TAF1 RSPH4A CFTR NME8 DNAAF4 LEP CCDC65 NADK2 CD55 COL11A2 NHLRC1 PEPD CFAP300 LTBP3 WAS DNAI1 TBCD IL2RG GFI1 NBN RSPH1 CCDC39 PMM2 ICOS TNFSF12 IFNGR1 CARD11 SFTPC DNAL1 OFD1 ZMYND10 IL21R FMO3 SLC35A1 PLOD1 ORC6 RAG2 CACNA1C GAS8 RYR1 CFAP298 GNPTAB TNFRSF13B KDM6A PANK2 RANBP2 CYBA USB1 UBB DOCK8 ADA DNAAF2 KMT2D SAMD9 MUC5B IL7R DNAAF1 ICOS RAG2 CARD11 PTPRC ALMS1 NOTCH3 NSMCE3 DNAI1 TNFRSF13C GRHL3 EGFR IL2RG DNAAF6 PNP DNAH5 SETBP1 CR2 CD3E ADA MASP2 SFTPA2 ACTA1 RAC1 TTC25 FCGR2A ZAP70 SPEF2 IGHM DNAAF5 NBN CD247 DDR2 CD19 ACADVL KIAA0586 TK2 BLNK ARMC4 SGCG RAG1 CXCR4 NCF1 SRP54 FOXP3 IRF8 CFAP221 RNU4ATAC KCNJ6 LRBA CD3D P4HTM SELENON CCDC114 TNFRSF13B PLG DCLRE1C SLC25A24 DCLRE1C ICOS IL7R FOXJ1 JAK3 IL2RG CASP8 RAG1 OSTM1 CFAP410 CCNO NCF2 UNC119 TNFRSF13C JAK3 RNF125 STK36 POLA1 CD19 CR2 DNAH1 RSPH3 RSPH9 CYBB DRC1 DCLRE1C CCDC103 DNAAF3 LRRC56 PIGN LRRC6 SP110 PRKCD ACP5 CCDC40 SLC35C1 BTK MTHFD1 PGM3 RAG1 TERT CHD7 CFB TGFB1 RNU4ATAC SMARCD2 NKX2-1 OFD1 ZBTB24 BTK DNAI2 WDR19 ZAP70 CD79B CD81 COL11A2 NFIX RAG2 ELANE AFF4 NFKB1 IL2RG TNFRSF13C TNFSF12 CCDC114 ADA GBA DNAJB13 RPGR CSPP1 RMRP EPM2A DNMT3B NFKB2 MCIDAS HYDIN
Protein Mutations 6
A2063G G551D K55R L460D R287Q S1009A
SNP 0